Last reviewed · How we verify
Cohort A: ORMD-0801
ORMD-0801 is an oral insulin capsule that mimics the natural insulin production process.
ORMD-0801 is an oral insulin capsule that mimics the natural insulin production process. Used for Type 1 diabetes, Type 2 diabetes.
At a glance
| Generic name | Cohort A: ORMD-0801 |
|---|---|
| Also known as | Oral Insulin |
| Sponsor | Oramed, Ltd. |
| Drug class | oral insulin |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
ORMD-0801 works by using a proprietary technology to deliver a liquid insulin formulation in a capsule, which is then absorbed in the gut and released into the bloodstream, mimicking the natural insulin production process. This allows for a more physiological and sustained insulin release, potentially reducing the risk of hypoglycemia and improving glycemic control.
Approved indications
- Type 1 diabetes
- Type 2 diabetes
Common side effects
- Nausea
- Abdominal pain
- Diarrhea
- Vomiting
- Hypoglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort A: ORMD-0801 CI brief — competitive landscape report
- Cohort A: ORMD-0801 updates RSS · CI watch RSS
- Oramed, Ltd. portfolio CI